Subscribe to stay informed!
A Devon pharmaceutical company is working on cannabinoid therapies to treat genetic conditions. In the meantime, Zynerba Pharmaceuticals is planning a reverse stock split by…
At the start of the week, the stock market entered bear territory for the first time since 2020, further pushing down many local companies that…
Zynerba Pharmaceuticals, a clinical-stage pharmaceutical company based in Devon, is testing a CBD gel to help treat autism, writes Queen Muse for Philadelphia magazine…
Devon-based Zynerba Pharmaceuticals saw its shares surge after it received a U.S. patent for its cannabidiol (CBD) gel to treat Autism Spectrum Disorders…
Devon-based Zynerba Pharmaceuticals has received “Fast Track” status from the FDA for its synthetic cannabidiol drug intended to treat symptoms associated with Fragile X…
Devon’s Zynerba Pharmaceuticals, which develops synthetic cannabinoid therapies, is focusing on several rare and near-rare neurological and psychiatric disorders that have unmet medical…
For Devon’s Zynerba Pharmaceuticals, the switch to a smaller patch for pain treatment using a synthetic cannabinoid has bumped back the company’s target…
It has been a good week for Zynerba Pharmaceuticals, as the Devon based company received very positive results from the first phase of testing on…
A synthetic medical marijuana pioneer recently transplanted in Devon is experiencing an exciting high this week as it prepares to go public with 10 years…
Richard A. Baron is now vice president and chief financial officer at Zynerba Pharmaceuticals, Inc. of Radnor, a specialty pharmaceutical company that has invested $13…
Before we send you to this site, please subscribe to our daily newsletter.